ArticleCancer science2021

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.

Meijing Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.